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Abstract
Methylation of cytosines at CpG sites is a common epigenetic DNA modification that can be measured by a large number of
methods, now even in a genome-wide manner for hundreds of thousands of sites. The application of DNA methylation
analysis is becoming widely popular in complex disorders, for example, to understand part of the ‘‘missing heritability’’. The
DNA samples most readily available for methylation studies are derived from whole blood. However, blood consists of many
functionally and developmentally distinct cell populations in varying proportions. We studied whether such variation might
affect the interpretation of methylation studies based on whole blood DNA. We found in healthy male blood donors there is
important variation in the methylation profiles of whole blood, mononuclear cells, granulocytes, and cells from seven
selected purified lineages. CpG methylation between mononuclear cells and granulocytes differed for 22% of the 8252
probes covering the selected 343 genes implicated in immune-related disorders by genome-wide association studies, and
at least one probe was differentially methylated for 85% of the genes, indicating that whole blood methylation results
might be unintelligible. For individual genes, even if the overall methylation patterns might appear similar, a few CpG sites
in the regulatory regions may have opposite methylation patterns (i.e., hypo/hyper) in the main blood cell types. We
conclude that interpretation of whole blood methylation profiles should be performed with great caution and for any
differences implicated in a disorder, the differences resulting from varying proportions of white blood cell types should be
considered.
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Introduction
DNA methylation is the covalent addition of a methyl group in
the position 5 of a cytosine (C) when this nucleotide occurs next to
a guanine (G) forming a CpG site. There are around 28 million
CpG sites in the human genome. Depending on the chromosomal
region, cell type, developmental stage, alleles and parent-of-origin,
a CpG site can be methylated, unmethylated or hemi-methylated.
DNA methylation is involved in regulation of transcriptional
repression and gene silencing. Together with other epigenetic
mechanisms, DNA methylation functions as a switch that turns
relevant genes on and off, a mechanism that is crucial in
development, differentiation and homeostasis [1]. Certain CpG
sites are highly methylated in hematopoietic progenitors but
become unmethylated during differentiation [2,3,4]. There is also
a small number of genes that gain cell specific methylation when
the embryonic stem (ES) cells differentiate into the three germ
layers [5]. The search for those methylated and/or unmethylated
CpG sites that may categorize tissues and cell populations have
been under extensive research for more than two decades [6,7]. It
is known that cell specific DNA methylation patterns convey ‘‘cell
memory’’, which is transmitted to the progeny by mitosis [8].
Therefore, every differentiated cell type has CpG sites that are
specifically methylated or unmethylated for that specific lineage
but not for others [2,9].
There is currently extensive research ongoing aiming at the
identification of specific changes in DNA methylation that may
contribute to human diseases. Alterations in DNA methylation
have been shown to cause monogenic disease such as Rett
syndrome [10], and mediate genomic instability, silencing of
tumor-suppressor genes and hyper-methylation of CpG island
shores that may lead to the inception and progression of cancer
[11]. Results of genome wide association studies together with the
marked increase in the prevalence of several complex diseases
during the last decades, for example asthma and allergy, suggests
that other mechanisms such as epigenetics, including DNA
methylation, may also be involved [12,13]. These hypotheses
have been supported by the differential effect of genetic
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41361
polymorphisms depending on parent-of-origin [14], DNA meth-
ylation differences in disease-discordant monozygotic twins
[15,16,17], differences in DNA methylation related to environ-
mental exposures [18,19], and DNA methylation differences in
affected versus non-affected tissues [20,21]. Given the limitations to
obtain large number of samples from affected tissues, blood is an
attractive, easy and available source of DNA. Studies suggest that
DNA methylation differences can be detected in the blood of
patients with cancer, even for solid tumors [22,23,24]. There is an
increasing number of publications comparing differences in DNA
methylation in whole blood between cases and controls for
complex diseases [25,26,27,28]. Topperoff et al found a specific
methylation pattern in whole blood from patients with Type 2
diabetes that could be detected prior the onset of the disease [27].
In addition, differences in DNA methylation were identified in
leukocytes of mothers having children with congenital heart
defects [25]. Importantly, cell heterogeneity may act as a
confounder when measuring DNA methylation in whole blood
and the possibility to adjust for differential cell counts is being
explored [27]. However, it is still unclear whether this strategy
suffices to correct for inter-individual variation, lineage relation-
ships (myeloid versus lymphoid), and potential effects of prominent
methylation differences in less frequent cell populations (e.g. B
cells, eosinophils, T regulatory cells).
The aims of this study were 1) to identify differentially
methylated CpG sites globally in purified blood cells in connection
with their genomic distribution; 2) to identify genes harboring the
differentially methylated CpG sites and their connections with cell
lineage and functions; and 3) to compare the DNA methylation
profiles in a selection of candidate genes for complex inflammatory
diseases among blood cell populations.
Results
General description of cell populations
Six healthy male blood donors, age 38613.6 years, were
included in the study. From each individual, global DNA
methylation levels were analyzed in whole blood, peripheral blood
mononuclear cells (PBMC) and granulocytes as well as for seven
isolated cell populations (CD4+ T cells, CD8+ T cells, CD56+ NK
cells, CD19+ B cells, CD14+ monocytes, neutrophils, and
eosinophils, Figure 1). The differential cell count in whole blood
was similar for all six donors as well as the purities of sorted cell
populations as determined by flow cytometry (Figure S1, Ta-
ble S1). The purities based on surface cell markers ranged from
lowest 81.8618.8% for eosinophils to highest 97.861.7% for
neutrophils (Table S2).
DNA methylation differences reflect cell lineages rather
than inter-individual differences
Global DNA methylation was analyzed using the Illumina
Infinium 450K microarray platform [29]. When comparing all the
cell populations against each other, there were large variations in the
number of differentially methylated CpG sites (Table 1). These
differences were reflected in a clear clustering of all studied cell
populations according to their expected hematopoietic lineagewhen
using the median M-value from each cell population (Figure 2A).
Furthermore, a principal component analysis including all individ-
ual observations (n = 60) showed that theDNAmethylation patterns
differ more between cell populations than between individuals
(Figure 2B). The distribution of themeanM-values and the standard
deviations were similar for all cell populations, further supporting
the low inter-individual variance in this study (Figure S2). Surpris-
ingly, CD19+ B cells clustered separately from the other lymphoid-
derived cells (Figure 2A and B).
Since we were interested in whether whole blood is a valid
source for DNA methylation analyses, all the following analyses
were restricted to compare each cell population to whole blood
(see methodology section). In order to select the CpG sites of
highest interest, we also restricted our focus on the significantly
differentially methylated sites with a differential methylation call,
as defined by the gamma fit model (‘‘unmethylated’’, ‘‘marginal’’,
‘‘methylated’’). This analysis revealed that in the myeloid cell
populations, most of the CpG sites were unmethylated while for
the lymphoid populations, the majority was either marginal or
methylated (Table 2 and Figure 3A). When comparing the two
major leukocyte fractions in whole blood, PBMCs and granulo-
cytes, there was a large overlap of differentially methylated CpG
sites based on the median M-value (Figure S3). However, when
looking at the differentially methylated sites showing either
unmethylated or methylated state separately, the overlaps were
reduced (39% overlap for all, 4% for unmethylated and 12% for
methylated CpG sites, Figure S3). Furthermore, the genomic
distribution of the differentially methylated sites was studied in
each cell population. This revealed that most of the statistically
significant unmethylated and methylated CpG sites were located
in intragenic regions (gene bodies) and not associated with CpG
islands. There were no differences in this distribution between
PBMCs and granulocytes (Figure 3B) or for any of the purified cell
types (data not shown). Also, the data confirmed that CpG island
shores are more commonly harboring differentially methylated
CpG sites compared to CpG islands and CpG island shelves.
Differential DNA methylation is related to genes involved
in cell type-specific immune functions
Functional enrichment analyses were performed for the genes
showing significant unmethylated state in a specific cell population
and methylated state in whole blood. Gene ontology enrichment
suggested many expected cell specific categories for the cell types
analyzed (Figure 4). CD4+ and CD8+ T cells showed the most cell
specific enriched pathways including lymphocyte activation, T cell
receptor complex category, leukocyte activation and cell activa-
tion. CD56+ NK cells had enrichment in pathways belonging to
molecular signaling cascades. CD19+ B cells showed enrichment in
the cell specific pathway humoral immune response and the
category for plasma membrane part which included genes specific
for antigen presentation. Also for CD14+ monocytes, pathways
specific for the cells function such as leukocyte activation,
lymphocyte activation and B-cell activation were enriched. For
eosinophils, the enrichment was not directly related to cell type
specific functions but rather more characteristic for general cell
functions. With the criteria chosen for this analysis, i.e. comparing
the cell specific methylation to that in whole blood, no probes were
called unmethylated in CD16+ neutrophils and methylated in
whole blood.
The functional role of the differentially methylated genes was
further suggested by the cell-restricted patterns of DNA methyl-
ation in 30 genes according to their cell surface expression (based
on the CD nomenclature). In general, demethylation of CpG sites
was commonly found in lymphoid cells that were regarded as CD
positive, while for myeloid cells the patterns were more complex
and involved differences in single CpG sites or differences of
marginal status. An example is presented in Figure 5, showing the
methylation of the CD3 and CD14 genes in all the purified cells in
connection with their membrane expression as determined by flow
cytometry.
Genome Wide Methylation Profiles of Blood Cell
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Blood cell specific patterns of candidate genes in
inflammatory complex diseases
Recent advances within the genetic field have produced a large
number of candidate genes suggested to be involved in several
complex diseases. In order to analyze to which extent differences
in cell lineage may influence the DNA methylation profiles of
known susceptibility genes for inflammatory diseases, a group of
candidates were selected from the catalog of published genome-
wide association studies (http://www.genome.gov/gwastudies/)
[30]. The included diseases were asthma, atopy, atopic dermatitis,
Figure 1. Schematic presentation of the isolation protocol and purity of the cell populations as measured by flow cytometry.
Peripheral blood mononuclear cells (PBMC) and granulocytes were obtained by density gradient centrifugation and seven cell populations were
purified by magnetic sorting. Upper panel shows forward and side scatter which confirmed cell morphology and granularity. The lower panel shows
the overlay of cell surface markers for all the six donors. The purities of the cell populations were highly similar among all the six donors. Th cells =
CD4+ T cells, Tc cells = CD8+ T cells, NK cells = CD56+ NK cells, B cells = CD19+ B cells, Monocytes = CD14+ monocytes. Data analyses are based on
the comparison of all cell populations to whole blood.
doi:10.1371/journal.pone.0041361.g001
Figure 2. Clustering of cell populations in blood with regard to global DNA methylation. A) Hierarchical tree presenting the relationship
between cell populations based on median M-values from six donors. B) Principal component analysis of each individual sample showing specific
clustering based on cell population.
doi:10.1371/journal.pone.0041361.g002
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inflammatory bowel disease, rheumatoid arthritis, systemic lupus
erythematosus, Type 1 and Type 2 diabetes. In total, 343 genes
were selected and they were covered by 8252 probes. Of these
probes, 1865 (22.6%, Table S3) were differentially methylated
among cell types and they corresponded to 293 genes (85%,
Figure 6A). CD19+ B cells showed the largest variation for these
differentially methylated CpG sites. There was also a clear
difference in the methylation patterns when comparing lympho-
cytes (CD4+ T cells, CD8+ T cells and CD56+ NK cells) to the
myeloid cells (eosinophils, neutrophils and CD14+ monocytes).
Again, most of the significantly differentially methylated CpG sites
were located in intragenic regions (gene bodies, Figure 6B).
In depth analyses of the asthma associated genes encoding for
lymphotoxin alpha (LTA) and tumor necrosis factor (TNF) on
chromosome 6p21.3, showed that differentially methylated CpG
sites are enriched in the promoter region (59UTR, 1st exon) and
differ according to lymphoid versus myeloid lineages (Figure 7A).
Analyzing DNA methylation levels in whole blood for this region
would lead to misleading conclusions since myeloid cells are
methylated while lymphocytes are unmethylated. For the Type 2
diabetes candidate gene transcription factor 7-like 2 (TCF7L2) on
chromosome 10q25.3, the methylation pattern is similar along the
gene body but there are certain CpG sites that show unmethylated
state in CD14+ monocytes only (see arrows, Figure 7B). These sites
coincide with intron-exon boundaries in the 39end of the gene.
Methylation in the promoter CpG islands tends to be low and very
similar among all the cell types and for those CpG sites,
measurements in whole blood would reflect the methylation status
across cell populations. Largest variations in DNA methylation can
be seen along the CpG island shores and gene bodies (Figure 7A
and B).
Discussion
Summary of main findings
Here, we present for the first time a genome wide methylation
study covering approximately 450 000 CpG sites analyzed in
selected cell populations in blood obtained from the same
individual. Surprisingly, even though including only six healthy
adult male donors with an age range between 25 and 60 years, we
could see a clear clustering of the cell types according to their
lineage rather than by individual. We also found large differences
in DNA methylation between lymphoid and myeloid cells and
identified many CpG sites that were differentially methylated
between the purified cell populations. Interestingly, B cells showed
the most unique profile, suggesting that studies in B cells or cell
lines poorly reflect the overall blood cell methylation status. Many
genes covered by these differentially methylated CpG sites were
important for specific cell functions as highlighted by the gene
ontology analysis and the cell-specific demethylation patterns
according to their putative expression of surface markers. In
addition, we found differential methylation in selected candidate
genes for inflammatory diseases according to cell type. Impor-
tantly, regional differences occur within genes and may affect a cell
fraction or just a single cell population. Our results indicate that
caution should be exercised in interpreting results for a large
fraction of genes, specifically immune-related, when analyzing
whole blood DNA methylation results because the results will in
many cases depend on the blood differential count.
Myeloid versus Lymphoid lineage
Information on genome wide methylation patterns in human
blood cell populations is scarce [31,32,33,34]. Global analysis of
CpG sites associated with promoter regions has revealed some cell
specific differentially methylated sites by comparing monocytes
and granulocytes [2] as well as for pooled purified blood
populations [35]. In this study, we found enrichment of
unmethylated regions in granulocytes while PBMCs were in
general more methylated (Figure 3), confirming previous findings
in bone marrow progenitors of these cells [9]. In the more
common leukocytes, the neutrophils, approximately 85% of the
differentially methylated sites were unmethylated. These cells do
not divide and have an average lifespan of 5 days. The rapid
turnover that is required to replace these cells may be due to the
low requirements of the DNA methylation machinery, as
suggested by hypomorphs for Dnmt1 which have normal myelo-
poiesis but drastically reduced lymphopoiesis [36]. In monocytes,
differentially methylated CpG sites were more frequently un-
methylated (71%) and this may be related with the common
granulocyte/macrophage progenitor that is shared with the
granulocytes [4]. Comparative studies between CD34+ cells and
differentiated monocytes suggested that DNA methylation could
be a mechanism that silences the myeloid differentiation program
[2]. In contrast, lymphocytes live from 10 days to several years,











Monocytes Granulocytes Neutrophils Eosinophils
Whole Blood 23226 58980 125713 92238 97377 41063 27365 28581 52431
PBMC 23168 76847 33642 58485 98771 94601 87348 104631
CD4+ T cells 45015 38396 73318 115235 109933 106881 120620
CD8+ T cells 20629 98306 161524 164184 182881 192075
CD56+ NK cells 78880 157180 154816 146413 158727







PBMC – Peripheral blood mononuclear cells. Differentially methylated probes were defined by a linear model using the M-values.
doi:10.1371/journal.pone.0041361.t001
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Figure 3. Differentially methylated CpG sites compared between peripheral blood mononuclear cells (PBMC) and granulocytes. A)
The distribution of probes in the two populations defined by the calls unmethylated, margin and methylated. Data is based on a linear model
comparing the two principal cell populations to whole blood using M-values. The data was then subjected to a gamma fit model in order to group
the data into the defined calls. The value within the bars represents the percentage of the distribution within each population. B) The genomic
distribution of probes showing significantly differential methylation compared to whole blood for PBMC and granulocytes. Genomic regions were
defined according to the UCSC RefGene group (included in the Illumina annotation data). Probes are divided on the unmethylated and methylated
state according to the gamma fit model for both PBMC and granulocytes. Intergenic = site not annotated in a gene, TSS = transcription start site at
200–1500 bp, 59 region = 59UTR and 1st exon, Intragenic = gene body including introns and exons and, 39 region = 39UTR. UTR – untranslated
region.
doi:10.1371/journal.pone.0041361.g003
Genome Wide Methylation Profiles of Blood Cell
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comparison to whole blood
(M-values)** Unmethylated Marginal Methylated
PBMC 23226 5693 1.2–11.1 1.7% 25.8% 72.5%
CD4+ T-cells 58980 18537 1.2–51.9 9.4% 34.5% 56.1%
CD8+ T-cells 125713 32948 1.2–93.2 6.8% 59.7% 33.4%
CD56+ NK cells 92238 23484 1.1–54.0 6.5% 58.4% 35.1%
CD19+ B cells 97377 23245 1.2–221.8 15.0% 55.7% 29.3%
CD14+ Monocytes 41063 12625 1.2–70.4 71.2% 13.2% 15.6%
Granulocytes 27365 8815 1.2–13.1 85.3% 9.5% 5.2%
Neutrophils 28581 10808 1.2–14.5 84.2% 10.1% 5.7%
Eosinophils 52431 17723 1.2–117.2 65.8% 23.3% 10.8%
PBMC-Peripheral blood mononuclear cells. Differentially methylated probes were defined by a linear model using the M-values. M-value is the log2 ratio of the
intensities of methylated probe versus unmethylated probe, a measurement of how much more a probe is methylated compared to unmethylated [46]. *To extract the
probes with largest difference in methylation, a gamma fit model was applied to M-values in order to define the three calls: ‘‘unmethylated’’, ‘‘marginal’’ and
‘‘methylated’’. Significant probes sharing the same call in the two compared populations were removed. **Variation is based on the estimate of the log2-fold-change
corresponding to the effect obtained from the linear model, absolute M-values are presented. The percentages are based on the call distribution.
doi:10.1371/journal.pone.0041361.t002
Figure 4. Gene ontology enrichment for isolated cell populations. Gene ontology was performed using DAVID (http://david.abcc.ncifcrf.gov)
[47]. The human genome was used as background and the level of significance was set to p,0.05. The top ten enriched pathways are described for
genes showing significantly differentially methylated probes in comparison to whole blood where the cell population shows unmethylated state and
whole blood shows methylated state according to the gamma fit model. Red color indicates peripheral blood mononuclear cells (PBMC) and green
color indicates granulocytes.
doi:10.1371/journal.pone.0041361.g004
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undergo positive and negative selection across different tissues and
differentiate to subsets through cell divisions. It is possible that a
state skewed towards more methylation in the lymphocytes may be
favorable to keep cell memory during clonal expansion and to
regulate the fate in different subsets of lymphocytes (e.g. effector
versus memory cells).
The B cell
The main role of the B cell is antigen presentation and
production of antibodies, key components in the humoral immune
response. Interestingly, we found that CD19+ B cells cluster
separately from other lymphocytes and they show the largest
number of differentially methylated CpG sites (Figure 2B and 5A).
DNA methylation has previously been found to be of relevance in
the allelic exclusion of the Fab light chains and in the V(D)J
rearrangement of the immunoglobulin heavy chain locus [4].
However, we found many differentially methylated genes belong-
ing also to other pathways indicating a global pattern separating B
cells from other cell types in blood. Gene ontology categories
suggested that in addition to the predictable humoral response
genes, a large proportion of the enriched genes harboring
differentially methylated sites are involved in internalization and
presentation of antigens, which reflects a capital difference
between B cells and T lymphocytes. Therefore, at the DNA
methylation level, the B cells resemble an intermediate state
between the monocyte and the T lymphocytes in part for their role
as phagocytes and antigen presenting cells. Besides, the different
developmental stages of circulating B cells such as transitional B
cells, memory B cells and plasma cells, which have no counterparts
in T cells, may have contributed to the particular B cell pattern.
Regional effects of differential DNA methylation
Studies have shown that tissue-specific differentially methylated
regions are highly conserved in mammals [37,38] and located in
Figure 5. Differentially methylated sites are harbored by cell-specific genes but the connection between methylation status and
surface expression depend on the gene and lineage. The surface expression of CD3 and CD14 according to the methylation status of the
coding gene is presented. Demethylation of CpG sites was observed in T cells expressing the CD3 marker (upper panel). For CD14 the difference
between positive and negative cells involved cell-restricted marginal status in a context of demethylation (lower panel). Histograms (right) represent
the log fluorescence of the marker (x-axis) and the cell counts (y-axis). Peaks within the gray shaded gates represent positive populations. For CD14
two gates are presented, the ‘‘low’’ which include monocytes and a fraction of neutrophils and the ‘‘high’’ population of monocytes. m = membrane;
e* = positive or negative cell expression of the marker according to the Human Leucocyte Differentiation Antigens (HLDA) Workshop and CD
nomenclature (http://www.hcdm.org/Home/tabid/36/Default.aspx).
doi:10.1371/journal.pone.0041361.g005
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Figure 6. Differentially methylated CpG sites in candidate genes related to inflammatory diseases. A) Heatmap of 1865 probes
representing 293 candidate genes for selected inflammatory diseases showing differential methylation in blood cell populations. Candidate genes for
the diseases asthma, atopy, atopic dermatitis, inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, Type 1 and Type 2
diabetes were selected from the Genome wide association study atlas (http://www.genome.gov/gwastudies/) [30]. The heatmap is based on median
M-values. The M-value is calculated as the log2 ratio of the intensities of methylated probe versus unmethylated probe [46]. Blue color indicates low
DNA methylation while yellow represents high DNA methylation. WB = whole blood, CD4T = CD4+ T cells, CD8T = CD8+ T cells, CD56NK = CD56+
NK cells, CD19B = CD19+ B cells, CD14Mono = CD14+ monocytes. B) The genomic distribution of the differentially methylated probes associated
with inflammatory complex diseases according to the UCSC RefGene group (included in the Illumina annotation data). Intergenic = site not
Genome Wide Methylation Profiles of Blood Cell
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crucial regulatory areas such as 59UTRs and promoters as well as
in gene bodies [39]. We showed that differentially methylated sites
were more frequently located in gene bodies irrespective of
whether or not they were methylated or unmethylated (Figure 3C
and D) which is in agreement with Maunakea et al. They showed
that a great proportion of tissue and cell type specific DNA
methylation across gene bodies coincide with highly conserved
sequences. Methylation within these gene bodies can then regulate
intragenic promoter activity and therefore the alternative expres-
sion of splice variants [40]. Furthermore, recent findings in murine
immune cells show that differential DNA methylation occurs
primarily in CpG islands located inside gene bodies which are
infrequently annotated with promoter CpG islands or CpG island
shores [1]. The over-representation of differentially methylated
sites in gene bodies may explain why strong CpG islands can be
unmethylated and the gene remains transcriptionally inactive
while promoters with low CpG content are more frequently
methylated without precluding transcription [41]. The function of
these sites within gene bodies as well as those located in non-
coding RNAs remains to be investigated. Moreover, previous
findings using whole genome methylation sequencing of PBMC
[33] and B cells [32] support our finding that CpG sites in regions
of high density such as CpG island and 59UTR were more often
unmethylated, while CpG sites located in introns, 39 UTRs and
repetitive elements were methylated.
Blood cell specific patterns of candidate genes in
inflammatory complex diseases
DNA methylation has gained a lot of interest within the
studies of complex diseases. Some of the candidate genes
obtained from genome wide association studies are currently
being analyzed for DNA methylation in case-control datasets, but
it is unknown whether they are amenable to be analyzed in
whole blood. We analyzed a selection of candidate genes and
found that 22% of the CpG sites within these genes were
differentially methylated between cell types and B cells showed
the largest variation (Figure 6A). Detailed examples of gene
specific DNA methylation patterns in LTA, TNF and TCF7L2
(Figure 7) showed that many regions within a gene may be
unaffected by cell composition in whole blood and thus
independent of cell counts. However, there are site specific
changes that are highly influenced by cell type and these may be
the sites of greatest interest to study in relation to disease. For
example, the Type 2 diabetes candidate gene TCF7L2 has a
similar methylation pattern along the gene body but there are
CpG sites showing unmethylated state in monocytes only
(Figure 7B, see arrows). A study on tissue specific expression of
TCF7L2 isoforms showed that in blood, the isoform ‘ex7–8’ was
only expressed in monocytes [42]. This might suggest that the
regions we highlight could be regulating this tissue specific
expression. The current lack of information regarding cell
specificity imposes a limitation for the selection of CpG sites in
comparative studies of DNA methylation using candidate
approaches.
Conclusions
The number of CpG sites that are differentially methylated
between purified cells and whole blood and mixed fractions
(PBMCs and/or granulocytes) generally reflects the frequency of
the cell populations in both compartments, and consequently,
adjustment of DNA methylation levels by differential cell counts
may have some use in epidemiological studies. This is exemplified
in the comparison between monocytes versus whole blood; or
neutrophils versus granulocytes (Table 1) where both populations
are frequent and prominently represented in each other. However,
it should be considered that the relative contribution of the less
abundant cell populations to the estimates in whole blood are not
always in direct correlation with their frequency. For example the
eosinophils are rare cells in the circulation and therefore the
number of differentially methylated CpG sites compared to whole
blood is masked by the partial overlap with the granulocyte
compartment. Likewise, in many inflammatory diseases, the blood
cells only weakly relate to the tissue specific pattern of
inflammation. Together with the difficulties to draw a priori
inferences on the cell-specific methylation for any given CpG site,
these biological facts make candidate gene studies for DNA
methylation in whole blood challenging.
In conclusion, this study provides important insights to the
complex DNA methylation patterns defining specific cell types in
peripheral blood. The clear differences between DNA methylation
patterns in myeloid cells and lymphocytes as well as the distinct
methylation profile of B cells highlight the difficulties of
interpreting this type of analyses in whole blood. If performing
DNA methylation analyses using whole blood, the cell specific




This study was performed in accordance with the principles
expressed in the Declaration of Helsinki. The protocol was
approved by the local ethics committee at Karolinska Institutet.
All individuals signed a written informed consent to participate in
the study.
Study participants
Purified blood cell populations were obtained from six male
healthy blood donors (mean age 38613.6 years), previously
recruited within the MALF study [43]. The sampling was done
between July and October 2010 at the Fridhemsplan Blood Bank,
Stockholm. 450 mL of blood were collected from the median
cubital vein into transfusion bags containing citrate phosphate
dextrose (Terumo Corporation, Japan), stored at room tempera-
ture and processed within 24 hours.
Purification of blood cell populations
Two aliquots of whole blood were initially taken from the
transfusion bag: 1 mL placed in a cryovial and stored at 280uC
for further DNA extraction and, a 3 mL aliquot used for plasma
collection and cell counting (see flow cytometry paragraph below).
The blood was transferred into a sterile 175 cm2 cell culture flask
(Greiner Bio One, Germany), diluted up to 750 mL in PBS and
distributed in sterile tubes with porous barriers (LeucosepTM,
Greiner Bio One Cat. 227 290). PBMCs and granulocytes were
separated by density centrifugation on Ficoll-Paque PlusTM (GE
Healthcare, Sweden) at 400 g, 20uC during 30 minutes. PBMCs
were washed (3x) in PBS, re-suspended in 0.5% BSA-PBS, 2 mM
EDTA (pH 7.2) and then counted and analyzed for viability using
annotated in a gene, TSS = transcription start site at 200–1500 bp, 59 region = 59UTR and 1st exon, Intragenic = gene body including introns and
exons and, 39 region = 39UTR. UTR – untranslated region.
doi:10.1371/journal.pone.0041361.g006
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trypan dye exclusion (CountessH Automated Cell Counter,
Invitrogen, USA). Granulocytes were recovered from the cell
pellet of the density gradient and incubated (2x) with red blood cell
lysis buffer (150 mM NH4Cl, 100 mM KHCO3, 1 mM EDTA) at
4uC during 12 and 4 minutes, respectively. Afterwards, granulo-
cytes were washed (3x) in PBS, re-suspended in 0.5% BSA-PBS,
2 mM EDTA (pH 7.2), counted and evaluated for viability. An
aliquot of PBMCs and granulocytes (56106 cells, each) was stored
at 280uC for further DNA extraction. The remaining PBMCs
were distributed according to the input requirements for magnetic-
activated cell sorting (MACS, Miltenyi Biotech, Germany) to
obtain T cells, B cells, monocytes, and NK cells. These
populations were purified by positive selection using anti-CD4,
anti-CD8, anti-CD19, anti-CD14, and anti-CD56 antibodies
coupled to paramagnetic beads (Miltenyi Biotech, Germany).
Granulocytes were split in two fractions for neutrophil and
eosinophil purification. Neutrophils were obtained by positive
selection using anti-CD16 antibodies and eosinophils were
obtained using the untouched protocol (Eosinophil Isolation kit
II, Miltenyi Biotech, Germany). Cell separations were done
according to the manufacturers’ instructions on LS columns. After
purification, all populations were counted, aliquoted at ,56106
cells per vial, snap frozen and stored at 280uC until DNA
isolation. A replicate of 0.1–0.56106 cells was taken from each
population to validate purities by flow cytometry.
Flow cytometry
The purity of the populations was evaluated by immunophe-
notyping using four-color antibody panels (Table S4). Cells were
re-suspended in FACS buffer (0.1% BSA in PBS) at a final
concentration of 0.16106 cells per tube. Fc receptors were blocked
with 1 ml of normal mouse serum (Cat. X0910, Dako Cytomanion,
Denmark) during 10 minutes at 4uC. Optimized panels of
fluorochrome-conjugated monoclonal antibodies were added to
the cells, in a final volume of 100 ml and incubated for 30 minutes
at 4uC. Every staining included the unstained sample and the
corresponding panels of isotype controls to set the gates for positive
and negative populations. After staining, cells were washed and
fixed in 200 ml of 2% formaldehyde in PBS. Data were acquired
using a FACS Calibur (BD Biosciences, USA), to at least 5000
events per population and analyzed by Flow Jo v7.6.3 (Tree Star
Inc., USA). The achieved purities per cell population are
presented in Tables S1 and S2.
DNA extraction, bisulfite treatment and DNA methylation
measurement
Genomic DNA was isolated from cell pellets using the QIAmp
DNA Micro Kit (QIAGEN, Germany) according to the manu-
facturer’s instructions. DNA concentration was measured by
spectrophotometry (NanoDrop ND-1000 Spectrometer, Thermo
Scientific, USA) and DNA quality was estimated with the ratio of
absorbance A260/A280. Sixty samples of genomic DNA [500 ng]
were bisulfite converted with the EZ-96 DNA Methylation Kit
(Zymo Research Corporation, USA) according to the manufac-
turer’s instructions. Array-based specific DNA methylation anal-
ysis was performed with the Infinium Human Methylation 450K
bead chip technology (Illumina, USA). All samples were analyzed
for more than 450,000 CpG sites at single nucleotide resolution
with 99% coverage of RefSeq genes and 96% coverage of CpG
islands. Probes were distributed in CpG island shelves, CpG island
shores, CpG islands, promoter regions 59UTRs, first exon, gene
body and 39UTRs. Additional CpG sites previously described as
differentially methylated across tissue types, associated with
tumors, located in FANTOM4 promoters, in DNase hypersensi-
tive sites and/or miRNA promoter regions were also analyzed.
Bisulfite-treated genomic DNA was whole-genome amplified,
hybridized to HumanMethylation450 BeadChips (Illumina,
USA) and scanned using the Illumina iScan at the Bioinformatic
and Expression Analysis (BEA) Core Facility of the Karolinska
Institutet. The intensity of the images was extracted with the
GenomeStudio Methylation Software Module (v 1.9.0, Illumina,
USA). The Infinium methylation data are available in the Gene
Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.
gov/geo/), under accession number GSE35069. Data and
illustration tool for methylation at user-specified locations are also
available on the website: http://publications.scilifelab.se/kere_j/
methylation.
QC analysis and data validation
Quality control was conducted in GenomeStudio software
(v2011.1) using the methylation module (v1.9.0) according to the
manufacturer’s recommendations (Illumina, USA). Briefly, the
controls included assessment of DNP and Biotin staining,
hybridization, target removal, extension, bisulfite conversion, G/
T mismatch, and negative and non-polymorphic controls. The
various controls indicated overall good quality of DNA prepara-
tions and chip performances.
Bioinformatics analysis
The raw data were imported into R v. 2.13 and analyzed with
the Bioconductor lumi package [44]. The data was further visually
inspected for quality check, adjusted for color channel imbalance
and background noise, and normalized according to the quantile
method. Probe-wise differential methylation was assayed by linear
model and, subsequently, the pair-wise comparisons of each cell
type versus whole blood were tested by Bayesian moderated t-test
on the normalized matrix of intensity values (M values) [45]. The
M-value is calculated as the log2 ratio of the intensities of
methylated probe versus unmethylated probe and describes a
measurement of how much more a probe is methylated compared
to unmethylated [46]. A value close to 0 indicates a similar
intensity between the methylated and unmethylated probes, which
means the CpG site is about half-methylated [46]. Positive M-
values mean that more molecules are methylated than unmethy-
lated, while negative M-values mean that more molecules are
unmethylated. The M values give higher resolution than the beta
values for extreme methylation levels, whereas at low methylation
Figure 7. DNA methylation levels across the gene regions in purified cell populations for candidate genes. DNA methylation is defined
by the M-values for each cell population at a given CpG site. The M-value is calculated as the log2 ratio of the intensities of methylated probe versus
unmethylated probe and describes a measurement of how much more a probe is methylated compared to unmethylated [46]. Negative numbers
represent unmethylated and positive numbers represent methylated. Every cell population correspond to a vertical bar which is listed from left to
right as peripheral blood mononuclear cells (PBMC), CD4+ T cells, CD8+ T cells, CD56+ NK cells, CD19+ B cells, CD14+ monocytes, granulocytes,
neutrophils, eosinophils and whole blood. Lymphoid cells are colored in red bars, myeloid cells are colored in green bars and whole blood is
represented by black bars. A) the asthma candidate genes lymphotoxin alpha (LTA) and tumor necrosis factor (TNF), and B) the Type 2 diabetes
candidate gene transcription factor 7-like 2 (TCF7L2), black arrows indicate regions with cell type specific pattern for monocytes. TSS = transcription
start site at 200–1500 bp; UTR = untranslated region, gene body including introns and exons.
doi:10.1371/journal.pone.0041361.g007
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levels they are colinear. Probes with Benjamini and Hochberg
corrected p-value ,0.01 were considered to be significant.
Moreover, probe-wise methylation status (i.e. ‘‘Methylated’’,
‘‘Marginal’’, ‘‘Unmethylated’’) was computed by fitting the
normalized data to a two component Gamma mixture model. In
brief, in each sample separately, the ratio between Cy3 and Cy5
signal for each probe defines the status (methylation %). The
gamma fit model returns the probability that this signal ratio is
balanced (‘‘marginal’’) or otherwise shifted towards Cy3 (‘‘un-
methylated’’) or Cy5 (‘‘methylated’’) signal. In each pair-wise
comparison, the significant probes with different methylation calls
between each cell type and whole blood were considered for
further analysis.
Gene ontology analysis
Gene ontology enrichment of genes containing differentially
methylated CpG sites was performed using The Database for
Annotation, Visualization and Integrated Discovery v6.7 (DAVID,
http://david.abcc.ncifcrf.gov) [47]. Analyses were based on a
hypergeometric test with a p-value ,0.01. Categories with a p-
value ,0.05 were considered significant and the top ten pathways
are presented. Analyses were performed on the lists of genes
showing unmethylated state in a selected cell population and
methylated in whole blood using the whole human genome as
background.
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Figure S2 Distributions of the mean M-values and standard
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mined by flow cytometry.
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